Important Safety Information
Adverse events should be reported. Reporting forms and information can be found at www.gov.uk/yellowcard.
Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or firstname.lastname@example.org
Contraindications: AJOVY® is contraindicated in patients with hypersensitivity to fremanezumab or to any of the excipients1
Hypersensitivity Reactions: Hypersensitivity reactions were reported with fremanezumab in less than 1% of patients in clinical trials. If a hypersensitivity reaction occurs, discontinuation of fremanezumab administration should be considered and appropariate therapy should be initiated.1 During post-marketing surveillance there have been rare reports of anaphylaxis within the European Union (these are currently under review by Medicines and Healthcare products Regulatory Agency.
Adverse Events: The most common adverse reactions were injection site reactions1
AJOVY® is indicated for prophylaxis of migraine in adults who have at least four migraine days per month1
Please see the Prescribing Information for AJOVY®